{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:42:26Z","timestamp":1792057346337,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.maturitas.2026.108878","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:45:59Z","timestamp":1771573559000},"page":"108878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Adherence to and tolerance of low-dose tamoxifen versus standard-dose tamoxifen in women at increased risk of breast cancer"],"prefix":"10.1016","volume":"208","author":[{"given":"Mariya O.","family":"Pogorelova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Buzzard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley R.","family":"Salonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Klassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.maturitas.2026.108878_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"18","key":"10.1016\/j.maturitas.2026.108878_bb0010","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and bowel project P-1 study","volume":"90","author":"Fisher","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108878_bb0015","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1056\/NEJMsr1407164","article-title":"Atypical hyperplasia of the breast--risk assessment and management options","volume":"372","author":"Hartmann","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.maturitas.2026.108878_bb0020","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/1097-0142(19930215)71:4<1258::AID-CNCR2820710415>3.0.CO;2-I","article-title":"Breast cancer risk associated with proliferative breast disease and atypical hyperplasia","volume":"71","author":"Dupont","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2026.108878_bb0025","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jss.2021.03.063","article-title":"Upgrade rate of atypical ductal hyperplasia: ten years experience and predictive factors","volume":"266","author":"Gagnon","year":"2021","journal-title":"J. Surg. Res."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108878_bb0030","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10549-024-07261-6","article-title":"Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants","volume":"205","author":"Chung","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"issue":"33","key":"10.1016\/j.maturitas.2026.108878_bb0035","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.2015.61.4743","article-title":"Lobular carcinoma in situ: a 29-year longitudinal experience evaluating Clinicopathologic features and breast Cancer risk","volume":"33","author":"King","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.maturitas.2026.108878_bb0040","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/modpathol.2010.56","article-title":"Intraductal proliferative lesions of the breast: morphology, associated risk and molecular biology","volume":"23","author":"Ellis","year":"2010","journal-title":"Mod. Pathol."},{"issue":"5","key":"10.1016\/j.maturitas.2026.108878_bb0045","doi-asserted-by":"crossref","first-page":"511","DOI":"10.6004\/jnccn.2006.0041","article-title":"Evolving concepts in the management of lobular neoplasia","volume":"4","author":"Anderson","year":"2006","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"5","key":"10.1016\/j.maturitas.2026.108878_bb0050","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.amjsurg.2018.06.013","article-title":"Ductal carcinoma in situ current trends, controversies, and review of literature","volume":"216","author":"Hong","year":"2018","journal-title":"Am. J. Surg."},{"issue":"4","key":"10.1016\/j.maturitas.2026.108878_bb0055","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqac027","article-title":"Ductal carcinoma in situ of breast: from molecular etiology to therapeutic management","volume":"163","author":"Hophan","year":"2022","journal-title":"Endocrinology"},{"issue":"9169","key":"10.1016\/j.maturitas.2026.108878_bb0060","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(99)05036-9","article-title":"Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and bowel project B-24 randomised controlled trial","volume":"353","author":"Fisher","year":"1999","journal-title":"Lancet"},{"issue":"9336","key":"10.1016\/j.maturitas.2026.108878_bb0065","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the international breast Cancer intervention study (IBIS-I): a randomised prevention trial","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.maturitas.2026.108878_bb0070","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jnci\/djk049","article-title":"Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial","volume":"99","author":"Cuzick","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"issue":"15","key":"10.1016\/j.maturitas.2026.108878_bb0075","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.2002.06.029","article-title":"American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition","volume":"20","author":"Chlebowski","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108878_bb0080","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s10549-018-4775-1","article-title":"Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews","volume":"170","author":"Hackett","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108878_bb0085","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.clbc.2018.10.008","article-title":"Beliefs about medication and uptake of preventive therapy in women at increased risk of breast Cancer: results from a multicenter prospective study","volume":"19","author":"Thorneloe","year":"2019","journal-title":"Clin. Breast Cancer"},{"issue":"8","key":"10.1016\/j.maturitas.2026.108878_bb0090","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jamaoncol.2015.2247","article-title":"Tamoxifen Chemoprevention--End of the Road?","volume":"1","author":"Narod","year":"2015","journal-title":"JAMA Oncol."},{"issue":"19","key":"10.1016\/j.maturitas.2026.108878_bb0095","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1200\/JCO.18.01779","article-title":"Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia","volume":"37","author":"DeCensi","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.maturitas.2026.108878_bb0100","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1158\/1940-6207.CAPR-24-0324","article-title":"Improved uptake and adherence to risk-reducing medication with the use of low-dose tamoxifen in patients at high risk for breast Cancer","volume":"17","author":"Cornell","year":"2024","journal-title":"Cancer Prev. Res. (Phila.)"},{"issue":"24","key":"10.1016\/j.maturitas.2026.108878_bb0105","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","article-title":"Projecting individualized probabilities of developing breast cancer for white females who are being examined annually","volume":"81","author":"Gail","year":"1989","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.maturitas.2026.108878_bb0110","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/sim.1668","article-title":"A breast cancer prediction model incorporating familial and personal risk factors","volume":"23","author":"Tyrer","year":"2004","journal-title":"Stat. Med."},{"issue":"5","key":"10.1016\/j.maturitas.2026.108878_bb0115","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/01.CIR.0000154545.84124.AC","article-title":"Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial","volume":"111","author":"Decensi","year":"2005","journal-title":"Circulation"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226000551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226000551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T21:26:03Z","timestamp":1779485163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512226000551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":23,"alternative-id":["S0378512226000551"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.108878","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence to and tolerance of low-dose tamoxifen versus standard-dose tamoxifen in women at increased risk of breast cancer","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.108878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108878"}}